GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced final, confirmatory results from the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial demonstrating that sotrovimab, an investigational SARS-CoV-2 monoclonal antibody, significantly reduced the risk of hospitalisation or death among high-risk adult outpatients with mild-to-moderate COVID-19.
GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab
June 21, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022